25 results
Thumbnail

D2.271 - The effect of Organic Light Emiting Diode(OLED) phototherapy in atopic mouse model

Thumbnail

D2.274 - Late-onset toxic epidermal necrolysis (TEN) associated with nivolumab: attention to possible cofactors

Thumbnail

D2.261 - Mental health and quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.265 - Standard dosage vs. increased dosage of non-sedating antihistamines in pharmacotherapy of chronic spontaneous urticaria

Thumbnail

D2.266 - Comparative Efficacy of Dupilumab, Janus Kinase Inhibitors, and Conventional Immunosuppressants on Neuropsychiatric Outcomes in Patients with Atopic Dermatitis: A Retrospective Cohort Study

Thumbnail

D2.267 - Real-World Clinical Outcomes of Chronic Urticaria Patients in Greece: Longitudinal Data from the CURE Registry

Thumbnail

D2.268 - Clinical characteristics and Therapeutic Management of Hereditary Angioedema due to C1-Inhibitor Deficiency: A Retrospective Cohort Study in Colombia

Thumbnail

D2.269 - Predictors of Poor Disease Control in Greek Patients with Chronic Urticaria: Real-World Evidence from the CURE Registry

Thumbnail

D2.270 - Clinical and Laboratory predictors of treatment response among adult Egyptian patients with Chronic Spontaneous Urticaria

Thumbnail

D2.272 - Long-Term Remission Patterns in Chronic Spontaneous Urticaria: A Real-Life Cohort Study

Thumbnail

D2.273 - The frequency of metal sensitisation in patients who are about to undergo joint replacement

Thumbnail

D1.105 - Real-Life Evidence of Type 2 Immunomodulation with Benralizumab: From Steroid-Dependent to Controlled Asthma

Thumbnail

D1.106 - Dupilumab-Induced Systemic Eosinophilic Immune Activation Mimicking an EGPA-Like Prodrome: A Case Report

Thumbnail

D1.108 - Optimization of phenotyping in severe T2-bronchial asthma

Thumbnail

D1.109 - Biologics selection algorithm for severe T2-bronchial asthma targeted therapy

Thumbnail

D1.110 - Long Term Mepolizumab in Type-2 CRSwNP: Marked Polyp Reduction, Symptom Relief, and Airway Benefits in Real World Comorbid Patients

Thumbnail

D1.111 - Tezepelumab reduces in patients with severe allergic asthma and rhinoconjunctivitis not only bronchial but also nasal and conjunctival symptoms – results from an exposure chamber study

Thumbnail

D1.112 - ILC2 Expansion as a Biomarker of Suboptimal Response to Dupilumab in Severe Asthma: Findings from the PRISM Study

Thumbnail

D1.113 - Effect of mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a real-world retrospective observational study

Thumbnail

D1.114 - Efficacy of Radical Endoscopic Surgery Combined with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps Complicated with Bronchial Asthma: A Real-World research